BUND FINANCE

BUND FINANCE › Stocks › PFE

Pfizer Inc. (PFE)

NYSE · Stock price, chart and technical analysis

US$27.54-0.5200 (-1.85%)

Data from Financial Modeling Prep · Nov 19, 2026, 4:01 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$28.06
OpenUS$27.92
Day rangeUS$27.44 – US$27.99
52-week rangeUS$23.62 – US$31.44
Market capUS$156.97B
Volume35.00M
50-day averageUS$28.83
200-day averageUS$27.02
Beta0.30
Last dividend per shareUS$1.72

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$81.3BUS$101.2BUS$59.6BUS$63.6BUS$62.6B
Net incomeUS$22.0BUS$31.4BUS$2.1BUS$8.0BUS$7.8B
EPS (diluted)3.855.470.371.411.36
Gross margin62.1%66.1%58.1%71.9%74.3%
Operating margin24.9%37.7%7.4%23.5%27.8%
Net margin27.0%31.0%3.6%12.6%12.4%
Free cash flowUS$29.9BUS$26.0BUS$4.8BUS$9.8BUS$9.1B
Total debtUS$37.0BUS$34.9BUS$70.8BUS$67.0BUS$67.4B
CashUS$1.9BUS$416.0MUS$2.9BUS$1.0BUS$1.1B

Compound annual growth: revenue -6.3% · net income -22.9% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E39.5x27.6x26.4x
EV / EBITDA15.3x13.6x16.3x
Operating margin23.8%—3.6%
Net margin6.3%—-0.0%
Debt / equity1.29—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Pfizer Inc.

SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
CEOAlbert Bourla
Employees75,000
IPO date1972-06-01

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of…

www.pfizer.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice